Integra LifeSciences Reports Third Quarter 2008 Financial Results
Nov 7, 2008 (GlobeNewswire via COMTEX News Network) --
Revenues for the Third Quarter Increase 24% to $167 Million
Cash Flow From Operations Increases to $27 Million
Announces Acquisition of Its Australian and New Zealand Distributor
PLAINSBORO, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the quarter ended September 30, 2008. Total revenues in the third quarter of 2008 were $167.0 million, reflecting an increase of $32.0 million, or 24%, over the third quarter of 2007.
"Integra posted strong results this quarter and in the first three quarters of the year," said Stuart Essig, Integra's President and Chief Executive Officer. "We are pleased with the underlying strength of our business, including both revenue growth and operating cash flow."
The Company reported a GAAP net loss of $15.3 million, or $0.54 per diluted share, for the third quarter of 2008, compared to GAAP net income of $9.7 million, or $0.33 per diluted share, for the third quarter of 2007. During the quarter, the Company recorded a compensation charge and an in-process research and development charge related to the acquisition of the Theken companies totaling $43.5 million. GAAP operating loss for the third quarter of 2008 was $22.9 million.
In addition to GAAP results, Integra reports adjusted net income and adjusted diluted earnings per share. A further discussion of these non-GAAP financial measures can be found below, and reconciliations of GAAP net income/(loss) to adjusted net income and GAAP diluted earnings/(loss) per share to adjusted diluted earnings per share for the quarters ended September 30, 2008 and 2007 appear in the financial statements attached to this release.
Adjusted net income for the third quarter of 2008, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $13.3 million, or $0.46 per diluted share. In the third quarter of 2007, adjusted net income was $11.3 million, or $0.39 per diluted share.
Integra generated approximately $27.1 million in operating cash flows in the quarter and has generated more than $45 million in operating cash flows year-to-date in 2008, a 40% increase over the same period in 2007.
Integra also announced today that it is launching a direct sales force in Australia and New Zealand through the acquisition of its longstanding distributor in those markets. Integra paid $4.1 million ($6.0 million Australian Dollars) at closing and may pay up to $2.1 million ($3.1 million Australian Dollars) in future payments based on the performance of the business during the three years after closing.
Excluding revenues from product lines acquired after the second quarter of 2007, total revenues grew 11% over the prior year period. Excluding eliminated product lines distributed for third parties and recently acquired product lines, total revenues grew approximately 13% over the prior-year period.
Beginning this quarter Integra will present its revenues in three categories: Integra NeuroSciences, Integra Orthopedics, and Integra Medical Instruments. We have presented a break-out of historical revenues into these three categories in the "Events and Presentations" page of the Investor Relations section of our website. These categories have been chosen to better reflect the markets into which our products are sold and replace the previously reported revenue categories.
Integra NeuroSciences revenues grew by 20% to $68.0 million from $56.7 million in the prior-year period. NeuroSciences revenues were strong across all major product lines, with ultrasonic aspirators, neuromonitoring, cranial stabilization, and duraplasty all recording double-digit growth.
Integra Orthopedic revenues, which include the Extremity Reconstruction, Integra OrthoBiologics, Integra Spine, and private label product lines, grew by 63% to $53.8 million from $33.0 million in the prior-year period. Recently acquired IsoTis and Theken Spine revenues contributed $16.2 million in the period. Extremity reconstruction products grew more than 20%. Private label revenues were essentially flat versus the prior year period.
"This new format for presenting our revenues highlights the strength of our growing orthopedics business," said Mr. Essig. "The extremities, orthobiologics, and spine franchises complement each other and benefit from our leading position in tissue engineering. Our acquisitions of IsoTis last year and Theken Spine this year and the expansion of Integra's extremities reconstruction sales organization reinforce our commitment to the high-growth areas of orthopedics."
Integra Medical Instruments revenues were essentially flat year-over-year at $45.2 million versus $45.3 million in the prior-year period. This category is comprised of the Jarit, Luxtec, Miltex, and several smaller product lines, including pain management. During 2008, we have integrated these businesses and eliminated underperforming and certain distributed product lines, which has tempered growth in this category for several quarters. Since May 2007, we have eliminated distributed product lines representing approximately 40% of the original revenues of the LXU business.
Gross margin on total revenues in the third quarter of 2008 was 61.5%. Cost of goods sold included $1.3 million of inventory fair value purchase accounting charges from the Theken acquisition, $1.2 million of charges from discontinued product lines, and $0.2 million of charges related to facility consolidations, manufacturing transfers, and systems integration. Together, these charges reduced the gross margin by 1.6 percentage points.
Research and development expense increased $28.2 million in the third quarter of 2008 to $34.7 million. Research and development expense in the third quarter of 2008 included a $25.2 million acquired in-process research and development charge related to the Theken acquisition.
Selling, general and administrative expense increased by $31.5 million to $87.7 million in the third quarter of 2008, or 52% of total revenue, compared to $56.2 million, or 42% of total revenue, in the third quarter of 2007. Selling, general and administrative expense for the third quarter of 2008 includes a compensation charge of $18.4 million related to the restricted stock units granted in connection with the extension of the term of our Chief Executive Officer's employment agreement in the third quarter of this year. We continue to leverage our selling, general and administrative expenses as a percentage of sales. We expect these expenses to decrease to between 39% and 41% of revenue in 2009, with the increased leverage of our larger selling organizations being partially offset by the inclusion of the recently acquired Theken companies.
We reported a $1.5 million increase in net interest expense to $3.9 million for the third quarter of 2008, primarily from increased borrowings under our credit facility to fund the purchase of the Theken companies in August and the repayment of our $120 million convertible notes in April 2008.
At September 30, 2008, our cash totaled $109.4 million, and we had $200 million in outstanding borrowings under our credit facility. On October 30, 2008, the Company borrowed an additional $60 million under our senior secured revolving credit facility for general corporate purposes.
Integra's Board of Directors recently approved a $75 million share repurchase authorization, which will expire on December 31, 2010. Integra did not repurchase any shares of common stock during the quarter.
The company has updated its fourth quarter and full year 2008 guidance and is introducing its guidance for the full year 2009. In accordance with usual practice, expectations for financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed. However, the company's guidance does reflect the acquisition of its distributor in Australia and New Zealand. The acquisition closed on October 31, 2008.
In the fourth quarter of 2008 and in 2009, Integra anticipates that it will incur various charges related to inventory purchase accounting and integration of Theken and the company's distributor in Australia and New Zealand. We also anticipate consolidation, manufacturing and distribution transfer, and system integration charges related to various projects including the continued transfer of manufacturing amongst various sites and Oracle implementation activities in our facilities. These anticipated charges are outlined in the "Reconciliation of non-GAAP adjustments -- guidance" table at the end of this release.
In the future we may record, or expect to record, certain additional revenues, gains, expenses or charges (such as acquisition-related charges, facility consolidation, manufacturing and distribution transfer and system integration charges, and certain employee termination and related costs) that we will exclude in the calculation of adjusted earnings per share for historical periods and in providing adjusted earnings per share guidance.
We have increased our revenue guidance for the full year 2008 to a range of $657 million to $665 million from $650 million to $663 million. This revised guidance reflects actual results for the first three quarters of 2008. Fourth quarter revenue guidance is unchanged at $177 million to $185 million. The company is also introducing revenue guidance of $735 million to $755 million for the full year 2009. As has been the case in the past, we expect revenues in the first quarter of 2009 to be 3-5% lower than the fourth quarter of 2008, and earnings to be disproportionately lower, and that the fourth quarter of 2009 will be the strongest quarter of the year.
We are also revising our GAAP and adjusted diluted earnings per share guidance. The new full year 2008 guidance reflects actual results for the first three quarters. 2009 GAAP guidance does not include the impact of the adoption of the Financial Accounting Standards Board ("FASB") issued Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments that May be Settled in Cash Upon Conversion ("FSP APB 14-1"). FSP APB 14-1 requires that the liability and equity components of convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) be separately accounted for in a manner that reflects an issuer's nonconvertible debt borrowing rate. The company expects to provide guidance on the impact of the new standard in 2009.
We expect GAAP diluted earnings per share in the range of $0.96 - $1.01 for full year of 2008 and $0.60 - $0.65 for the fourth quarter of 2008. For full year 2009, we anticipate GAAP diluted earnings per share within the range of $2.24- $2.44.
We are updating full year 2008 adjusted diluted earnings per share guidance to within a range of $2.14 - $2.19 based on for third quarter results and the beneficial impact of a 31% expected full year adjusted income tax rate. Fourth quarter 2008 adjusted diluted earnings per share guidance remains unchanged at $0.60-$0.65. For full year 2009 adjusted diluted earnings per share is expected to be in the range of $2.35 - $2.55.
The Company expects to incur approximately $4.1 million, or $0.08 per share, of share-based compensation expense associated with FAS 123R in the fourth quarter of 2008 and approximately $4.0 million, or $0.08 per share, on a quarterly basis for 2009. This non-cash compensation expense is included in both the GAAP and adjusted diluted earnings per share guidance for fourth quarter 2008 and 2009 provided above.
We have scheduled a conference call for 9:00 am ET Monday, November 10, 2008, to discuss the financial results for the fourth quarter of 2008 and forward-looking financial guidance. The call is open to all listeners and will be followed by a question and answer session. Access to the live call is available by dialing (913) 312-1270 or through a listen-only webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through November 24, 2008 by dialing (719) 457-0820 (access code 8405173) or through the webcast accessible on our website.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (http://www.Integra-LS.com).
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect the Company's judgment as of the date of this release. Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, gross margin on product revenues, selling, general and administrative expenses, effective income tax rates, GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, acquisition and integration related costs and non-cash compensation expense associated with FAS 123R. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, the Company's inability to design or improve internal controls to address the disclosed material weaknesses; the impact upon operations of legal compliance matters or internal controls review, improvement and remediation; difficulties in controlling expenses, including costs of legal compliance matters or internal controls review, improvement and remediation; the impact of changes in management or staff levels; the Company's ability to maintain relationships with customers of acquired entities; physicians' willingness to adopt, and third-party payors' willingness to provide reimbursement for, the Company's recently launched and planned products; initiatives launched by the Company's competitors; the Company's ability to secure regulatory approval for products in development; the Company's ability to comply with and obtain approvals for products of human origin and comply with recently enacted regulations regarding products containing materials derived from animal sources; the Company's ability to integrate acquired businesses; the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the amount and timing of acquisition and integration related costs; the geographic distribution of where the Company generates its net income, the timing and amount of share-based awards granted to employees; and the economic, competitive, governmental, technological and other risk factors and uncertainties identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide adjusted revenues, adjusted net income and adjusted earnings per diluted share. Adjusted revenues consists of the following two measures: (i) growth in total revenues excluding product lines acquired after the second quarter 2007 and (ii) growth in total revenues excluding eliminated products lines distributed for third parties and recently acquired product lines. Adjusted net income consists of net income, excluding (i) acquisition-related charges, (ii) facility consolidation, manufacturing and distribution transfer and system integration charges, (iii) certain employee termination and related costs, (iv) charges associated with discontinued or withdrawn product lines, (v) charges related to restructuring European subsidiaries, (vi) intangible asset impairment charges, (vii) incremental professional and bank fees related to the delay in the filing of our 2007 Annual Report on Form 10-K, (viii) charges relating to the grant of restricted stock units in connection with the extension of the term of the CEO's employment agreement and (ix) the income tax expense/benefit related to these adjustments and the cumulative impact of changes in tax rates. Adjusted earnings per diluted share are calculated by dividing adjusted net income for earnings per diluted share by adjusted diluted weighted average shares outstanding. Because the Company reported a GAAP net loss in the third quarter of 2008, the calculation of GAAP diluted weighted average shares outstanding for the third quarter of 2008 excludes the effects of stock options and unvested restricted stock, as the effect of these equity awards would be anti-dilutive. The Company included the dilutive effects of these equity awards in the calculation of adjusted diluted weighted average shares outstanding used to calculate adjusted earnings per diluted share for the third quarter of 2008 because their effects are dilutive in relation to adjusted net income.
Integra believes that the presentation of adjusted revenues, adjusted net income and adjusted earnings per diluted share provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.Integra-LS.com.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except per share amounts)
Three Months Ended
September 30,
2008 2007
TOTAL REVENUE $ 167,028 $ 135,015
COSTS AND EXPENSES
Cost of product revenues 64,317 50,863
Research and development 34,718 6,546
Selling, general and administrative 87,660 56,241
Intangible asset amortization 3,224 3,029
--------- ---------
Total costs and expenses 189,919 116,679
Operating (loss)/income (22,891) 18,336
Interest income 399 1,518
Interest expense (4,249) (3,863)
Other income (expense), net (409) (325)
--------- ---------
(Loss)/income before income taxes (27,150) 15,666
Income tax (benefit)/expense (11,859) 5,993
--------- ---------
Net (loss)/income ($ 15,291) $ 9,673
Add back of after tax interest expense -- 3
--------- ---------
Net (loss) income for diluted earnings
per share ($ 15,291) $ 9,676
Diluted net (loss)/income per share ($ 0.54) $ 0.33
Weighted average common shares outstanding
for diluted net (loss)/income per share
28,121 29,314
Listed below are the items included in revenues and net income/(loss) that management excludes in computing the adjusted financial measures referred to in the text of this press release and further described under Discussion of Adjusted Financial Measures.
A. Growth in total revenues excluding product lines acquired after
the second quarter of 2007
Three Months Ended Increase
September 30, (Decrease)
2008 2007 $ %
-------- -------- -------- ----
($ in thousands)
Total revenues, as reported $167,028 $135,015 $ 32,013 24%
Less: Revenues of product
lines acquired after the
second quarter of 2007 17,637 -- 17,637 N/M
-------- -------- -------- ----
Revenues excluding recently
acquired product lines $149,391 $135,015 $ 14,376 11%
B. Growth in total revenues excluding eliminated product lines
distributed for third parties and recently-acquired product lines
Three Months Ended Increase
September 30, (Decrease)
2008 2007 $ %
-------- -------- -------- ----
($ in thousands)
Total revenues, as reported $167,028 $135,015 $32,013 24%
Less: Revenue from eliminated
product lines
distributed for
third parties 2,222 5,027 (2,805) (56%)
Revenues of product
lines acquired after
the second quarter
of 2007 17,637 -- 17,637 N/M
-------- -------- -------- ----
Revenues excluding eliminated
product lines distributed for
third parties and recently
acquired product lines $147,169 $129,988 $ 17,181 13%
C. Items included in GAAP net (loss)/income
Three Months Ended
September 30,
----------------------
($ in thousands) 2008 2007
--------- ---------
Acquisition-related charges 26,584 1,239
Facility consolidation, manufacturing and
distribution transfer and system
integration charges 238 93
Employee termination and related costs -- 130
Charges related to litigation matters
or disputes -- 138
Charge relating to grant of restricted
stock units in connection with extension
of the term of the CEO's
employment agreement 18,356 --
Charges associated with discontinued or
withdrawn product lines 1,207 --
Income tax expense (benefit) related to
above adjustments, the cumulative impact
of changes in tax rates, and
other adjustments (17,822) 59
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - HISTORICAL
(UNAUDITED)
(In thousands, except per share amounts)
Three Months Ended
September 30,
2008 2007
-------- --------
GAAP net (loss)/income ($15,291) $ 9,673
Non-GAAP adjustments:
Acquisition-related charges (a) 26,584 1,239
Facility consolidation, manufacturing and
distribution transfer and system
integration charges (b) 238 93
Employee termination and related costs (c) -- 130
Charges related to litigation matters
or disputes (d) -- 138
Charge relating to grant of restricted
stock units in connection with extension
of the term of the CEO's employment
agreement (e) 18,356 --
Charges associated with discontinued or
withdrawn product lines (f) 1,207 --
Income tax expense (benefit) related to
above adjustments, cumulative impact of
changes in tax rates and
other adjustments (g) (17,822) 59
-------- --------
Total of non-GAAP adjustments 28,563 1,659
-------- --------
Adjusted net income 13,272 11,332
Add back of after tax interest expense -- 3
-------- --------
Adjusted net income for diluted
earnings per share $ 13,272 $ 11,335
======== ========
Weighted average common shares outstanding
for GAAP diluted earnings per share 28,121 29,314
Non-GAAP adjustment for dilutive effects
of equity awards 927 --
Weighted averages common shares outstanding
for adjusted diluted earnings per share 29,048 29,314
-------- --------
Adjusted diluted net income per share $ 0.46 $ 0.39
======== ========
(a) 2007 - $1,239 recorded in cost of product revenues; 2008 -
$25,240 recorded in research and development, $1,283 in cost of
product revenues, $61 in selling general and administrative.
(b) 2007 - all recorded in selling general and administrative; 2008-
all in cost of product revenues
(c) 2007 - all recorded in selling general and administrative
(d) 2007 - all recorded in selling general and administrative
(e) 2008 - all recorded in selling general and administrative
(f) 2008 - all recorded in cost of product revenues
(g) 2007 - A $667 reduction to income tax expense during the third
quarter of 2007 was made to reflect what the income tax expense
would have been based upon a 34% effective income tax rate. The
adjusted 34% effective income tax rate for the third quarter of
2007 approximates the effective income tax rate that would have
been reported for the quarter after excluding the cumulative
impact of changes in actual statutory rates and estimated
effective income tax rates on prior quarters and certain
infrequently occurring items on the 2007 reported tax rate.
2008 - The amount is also reduced by $802 to reflect what the
income tax expense would have been based upon a 31% effective
income tax rate. The adjusted 31% effective income tax rate for
the third quarter of 2008 approximates the effective income tax
rate that would have been reported for the quarter after
excluding the cumulative impact of changes in actual statutory
rates and estimated effective income tax rates on prior quarters
and certain infrequently occurring items on the 2008 reported tax
rate.
2008 and 2007 - the remaining amount reflects the estimated
additional tax (expense)/benefit that the Company would record if
it used non-GAAP results instead of GAAP results in the
calculation of its tax provision, based on the statutory rate
applicable to jurisdictions in which the above non-GAAP
adjustments relate.
Condensed Balance Sheet Data (in thousands):
Sept. 30, Dec. 31,
2008 2007
-------- --------
Cash and marketable securities, including
non-current portion 109,339 57,339
Accounts receivable, net 111,081 103,539
Inventory, net 155,615 144,535
Bank line of credit 200,000 --
Convertible securities, current -- 119,962
Convertible securities, non-current 330,000 330,000
Stockholders' equity 321,594 260,429
Revenue categories
Three Months Ended Nine Months Ended
September 30, September 30,
(in thousands) 2008 2007 2008 2007
Medical Surgical Equipment $ 95,571 $ 85,873 $272,534 $247,177
Neurosurgical and
Orthopedic Implants 71,457 49,142 207,700 145,637
------------------- -------- -------- -------- --------
Total revenue $167,028 $135,015 $480,234 $392,814
============= ======== ======== ======== ========
Integra NeuroSciences $ 68,014 $ 56,678 $192,146 $176,610
Integra Orthopedics 53,848 33,035 155,996 99,483
Integra Medical Instruments 45,166 45,302 132,092 116,721
--------------------------- -------- -------- -------- --------
Total revenues $167,028 $135,015 $480,234 $392,814
============= ======== ======== ======== ========
Beginning with the third quarter 2008 earnings results, IntegraLifeSciences has recast its revenue results into three categoriesbased on the markets the company serves. The above table presentsthird quarter revenues in both the current and historical categories.In subsequent quarters the company will no longer present revenue inthe prior format.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE
(In thousands, except per share amounts)
Projected
Three Months Ended
31-Dec-08
Low High
GAAP net income $17,710 $19,150
Non-GAAP adjustments:
Acquisition-related charges 1,900 1,900
Facility consolidation, manufacturing and
distribution transfer and system
integration charges 680 680
Tax adjustment for full year 31% rate (1,740) (1,830)
Income tax (benefit) related to above
adjustments, cumulative impact of
changes in tax rates, and other adjustments (850) (850)
-------- --------
Total of non-GAAP adjustments (10) (100)
Adjusted net income $17,700 $19,050
Weighted average common shares
outstanding for diluted net
income per share 29,400 29,400
GAAP diluted net income per share $ 0.60 $ 0.65
Non-GAAP adjustments detailed above
(per share) $ 0.00 $ 0.00
-------- --------
Adjusted diluted net income per share $ 0.60 $ 0.65
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE
(In thousands, except per share amounts)
Projected Projected
Year Ended Year Ended
31-Dec-08 31-Dec-09
Low High Low High
GAAP net income $27,790 $29,230 $65,500 $71,500
Non-GAAP adjustments:
Acquisition-related charges 32,140 32,140 4,500 4,500
Facility consolidation,
manufacturing and
distribution transfer and
system integration charges 1,480 1,480 900 900
Incremental professional and
bank fees related to the
delayed 10-K filing 1,040 1,040 -- --
Charges associated with
discontinued or withdrawn
product lines 1,210 1,210 -- --
Charge relating to grant of
restricted stock units in
connection with extension
of the term of the CEO's
employment agreement 18,360 18,360 -- --
Tax adjustment for full
year 31% rate 460 370 -- --
Income tax expense (benefit)
related to above
adjustments (20,890) (20,890) (2,100) (2,100)
------- ------- ------- -------
Total of non-GAAP
adjustments 33,800 33,710 3,300 3,300
Adjusted net income $61,590 $62,940 $68,800 $74,800
Weighted average common
shares outstanding for
diluted net income
per share 28,800 28,800 29,300 29,300
GAAP diluted net income
per share $ 0.96 $ 1.01 $ 2.24 $ 2.44
Non-GAAP adjustments
detailed above (per share) $ 1.18 $ 1.18 $ 0.11 $ 0.11
------- ------- ------- -------
Adjusted diluted net income
per share $ 2.14 $ 2.19 $ 2.35 $ 2.55
IART-F
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President, Finance and
Administration, and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Karen Mroz-Bremner, Senior Manager, Corporate Development and
Investor Relations
(609) 936-6929
Karen.mroz-bremner@Integra-LS.com
(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX